b9189c77-004e-461a-9c15-b504b12a3030
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 83.4140999315537
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.480
- ANGIOGENESIS+0.450
- MYOGENESIS+0.410
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.390
- CHOLESTEROL_HOMEOSTASIS+0.340
- IL6_JAK_STAT3_SIGNALING+0.340
- APICAL_JUNCTION+0.330
- COAGULATION+0.320
- HYPOXIA+0.310
- INFLAMMATORY_RESPONSE+0.310
Top 10 suppressed
- G2M_CHECKPOINT-0.330
- PROTEIN_SECRETION-0.320
- ANDROGEN_RESPONSE-0.290
- MITOTIC_SPINDLE-0.240
- E2F_TARGETS-0.220
- SPERMATOGENESIS-0.200
- UV_RESPONSE_DN-0.170
- MYC_TARGETS_V1-0.160
- BILE_ACID_METABOLISM-0.130
- PEROXISOME-0.130
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | b2b53efa-8a7b-4871-b6bb-6ebfb5cc0cea | — | — | 0.892 |
| 2 | bb3dc2ff-a686-483e-8d3c-e06649462881 | — | — | 0.880 |
| 3 | 80bea63b-bc3a-4999-8c11-a35c92183cd7 | — | — | 0.873 |
| 4 | 1652b0a3-dc1d-4490-9632-07673713deb1 | — | — | 0.873 |
| 5 | d496ef4f-4716-4e6e-94e3-fce93b26d4ee | — | — | 0.867 |
| 6 | R170 | — | — | 0.867 |
| 7 | 82992 | EPN | Supratentorial EPN | 0.856 |
| 8 | BS_RXN5T5YT | Diffuse intrinsic pontine glioma | — | 0.852 |
| 9 | 6bc70f5c-fdba-4bef-865a-793b7782a107 | — | — | 0.849 |
| 10 | TCGA-60-2720-01A-01R-0851-07 | — | cohortSQ1 | 0.844 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 37 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.480 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.450 | Remibrutinib | — uncovered |
| MYOGENESIS | 0.410 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.390 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.340 | Remibrutinib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.340 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.330 | Inavolisib | — uncovered |
| COAGULATION | 0.320 | Binimetinib | — uncovered |
| HYPOXIA | 0.310 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.310 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.290 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.290 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.280 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.280 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.270 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.270 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.250 | Temsirolimus | — uncovered |
| PANCREAS_BETA_CELLS | 0.250 | Cobimetinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.200 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.200 | Idelalisib | — uncovered |